## Abstract Pompe's disease (glycogen storage disease type II) is an autosomal recessive myopathy caused by lysosomal Ξ±βglucosidase deficiency. Enzyme replacement therapy (ERT) is currently under development for this disease. We evaluated the morphological changes in muscle tissue of four children
Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy
β Scribed by Kevin C. Conlon; Walter J. Urba; John W. Smithii; Ronald G. Steis; Dan L. Longo; Jeffrey W. Clark
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 595 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
The occurrence of autoimmune disease in patients receiving alpha-interferon (a-IFN) therapy has been reported in several studies; these include autoimmune thyroiditis, thrombocytopenia, anemia, exacerbation of psoriasis, and the occurrence of sarcoidosis. The primary mechanism presumably is the emergence of autoantibodies to various structural proteins or receptors. Two studies have recently shown that a significant percentage of patients treated with recombinant alpha-interferon (r a-IFN) do form autoantibodies. The authors report six additional cases of development or exacerbation of autoimmune phenomena in patients receiving a-IFN therapy. Five of these patients developed symmetric polyarthropathies and the sixth had thyroiditis. The presence of a history of underlying autoimmune disease or baseline serologic abnormalities in five of these patients, including the patient who developed thyroiditis, suggests that a-IFN treatment can lead to the exacerbation of an underlying subclinical autoimmune process. Cancer 65:2237-2242,1990.
LPHA-INTERFERON (a-IFN) has established antitu-
A mor activity in a number of malignancies including chronic myelogenous leukemia, m e l a n ~m a , ~-~ renal cell ~a n c e r , ~, ~ non-Hodgkin's l y m p h ~m a , ~. ~ and multiple myeloma.'O~l' Now a-IFN is considered to be standard therapy for patients with hairy cell l e ~k e m i a , ' ~-' ~ and for acquired immune deficiency syndrome (AIDS)-associated Kaposi's sarcoma. l5 The common side effects associated with its use include fevers, chills, myalgia, arthralgia, fatigue, mild reversible bone marrow suppression, nausea, vomiting, and diarrhea.16 There have been reports of transient exacerbations of probable autoimmune diseases associated with recombinant human (rH) a-IFN therapy. Most of these reports have described autoimmune thyroiditis or autoimmune thrombocytopenia although autoimmune hemolytic anemia, exacerbation of psoriasis, the occurrence of sarcoidosis, and possible cellmediated suppression of hematopoiesis have also been re-Two recent studies have shown a high fre-I
π SIMILAR VOLUMES
Background: Concentrations of proinflammatory cytokines are increased in the intestinal mucosa of patients with active Crohn's disease (CD). In a prospective study we investigated whether cytokines can predict long-term remission (ΟΎ6 months) in patients with steroid-refractory CD receiving treatment
## Abstract This study investigated whether domperidone could improve gastrointestinal symptoms in patients with Parkinson's disease who were receiving levodopa therapy. A total of 11 patients were studied. Following a baseline gastric emptying test, patients were treated with a starting dose of do
Whether sustained biochemical response and absence of serum HCV RNA in the 6-12 months following suspension of interferon-β£ (IFN-β£) therapy reflect definitive viral clearance in patients with chronic hepatitis C virus (HCV) infection is controversial. To obtain more information on this topic, HCV RN
## Abstract Natural killer (NK) cells are implicated in the regulation of a protective immune response in patients chronically infected with hepatitis C virus (HCV), but effects of interferonβΞ±/ribavirin therapy on NK cell subsets and the consequences of viral clearance during therapy remain unclea